CD reports grants from European Commission H2020, German Cancer Aid Translational Oncology, German Breast Group, during the conduct of the study; personal fees from Novartis, Roche, MSD Oncology, Daiichi Sankyo, AstraZeneca, Molecular Health, and Merck, and grants from Myriad, outside the submitted work. CD is the cofounder of Sividon diagnostics. CD has a patent VMScope digital pathology software with royalties paid, a patent WO2020109570A1-cancer immunotherapy pending, and a patent WO2015114146A1 and WO2010076322A1-therapy response issued. SL reports grants or fundings from Amgen, AstraZeneca, Celgene, Novartis, Immunomedics, Pfizer, Roche, DSI Trevor, Vifor, Abbvie, Cepheid, Seagen, and VM Scope; receives payment or honoraria from AstraZeneca, Roche, Novartis, Pfizer, Prime/Medscape, Puma, and Samsung; has planned patents, issued or pending from EP14153692.0; reports participation on an Advisory Board from Amgen, AstraZeneca, DSI, Roche, Merck, Pfizer, BMS, SeaGen, Eirgenix, Celgene, Abbvie, Lilly, GlaxoSmithKline, and Pierre Fabre; is part of a leadership or fiduciary role from BIG. VN declares no competing interests.